ALRN News and Press, Aileron Therapeutics Inc. From 09/21/20

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC&#x...

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, including ...

Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects -- Positive interim dose optimization data from proof-of-concept Phase 1b study, reported in second quarter 2020 Additional second quarter ...

Nano cap Aileron Therapeutics ( ALRN +28.2% ) jumps on an 8x surge in volume in reaction to its announcement that it has completed enrollment in the dose optimization expansion cohort in its ongoing open-label Phase 1b clinical trial of lead candidate ALRN-6924, in development for the pr...

Are These Penny Stocks On Your Watch List With earnings season in full-swing, biotech penny stocks are in focus. Coronavirus isn’t going anywhere anytime soon and we’ve now begun seeing the progress from Q2. Some companies have experienced strong windfalls and began expansive i...

Aerpio Pharmaceuticals (NASDAQ: ARPO ) +61%  on announcing a second clinical trial with funding from MTEC. More news on: Aerpio Pharmaceuticals, Inc., Whiting Petroleum Corporation, Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...

MyoKardia reports initiating trial for invasive septal reduction therapy MyoKardia Inc. ( MYOK ) announced that it has dosed the first person for the Phase 3 VALOR-HCM clinical trial. The study aims to provide direct clinical evidence of mavacamten’s capability to alleviate the re...

Aileron Therapeutics (NASDAQ: ALRN )   +8%  premarket, after the company completed enrollment in dose optimization expansion cohort of its Phase 1b study of ALRN-6924. More news on: Aileron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blai...

Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of AL...